Real-World Impact of Switching From Insulin Glargine (Lantus®) to Basaglar® and Potential Cost Saving in a Large Public Healthcare System in Saudi Arabia

• Asıl Yazarlar: Yazed AlRuthia (Yazar), Ohud H. Bahari (Yazar), Suliman Alghnam (Yazar), Ali M. Alrumaih (Yazar), Hassan Asiri (Yazar), Mohammed Alshammari (Yazar), Mansour Alhowimel (Yazar), Hana A. Al-Abdulkarim (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Frontiers Media S.A., 2022-06-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

BackgroundThe advent of Basaglar®, which is a biosimilar insulin glargine formulation for Lantus® has brought hope that it will result in similar outcomes and lower costs. However, some health practitioners raised some concerns about the therapeutic equivalence of this new biosimilar. Therefore, we...